Clinical Trial Update: MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial (MagnetisMM-32) evaluating Elranatamab for relapsed or refractory multiple myeloma, including patients previously treated with anti-CD3…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Elranatamab (elranatamab)

Snippet

Sponsor: Pfizer | Conditions: Multiple Myeloma | Phase 3 | Status: RECRUITING